Breaking News
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
March 21, 2018 - Second hand marijuana smoke can cause serious damage
March 21, 2018 - International study shows benefits of using MRI at the start of prostate cancer diagnosis
March 20, 2018 - Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
March 20, 2018 - ECG Patch Ups At-Home Afib Diagnosis in mSToPS Trial
March 20, 2018 - ROS-scavenging nanozymes for anti-inflammation therapeutics
March 20, 2018 - Genomics England announces appointment of global genomics pioneer as first CEO
March 20, 2018 - Test flight at German Aerospace Center in Cologne demonstrates functionality of deficopter
March 20, 2018 - Music therapy helps treat combat-related psychological injuries in military personnel
March 20, 2018 - Innovative psychotherapeutic treatment protocol for obsessive-compulsive disorders
March 20, 2018 - Weight loss after lap-band surgery alleviates arthritic knee pain
March 20, 2018 - New diabetes drug may help obese people shed body weight
March 20, 2018 - Novel Peanut OIT a Winner in Phase III Trial
March 20, 2018 - Can gene therapy be harnessed to fight the AIDS virus?
March 20, 2018 - Education and academic achievement can lessen effects of child abuse, neglect
March 20, 2018 - Researchers develop new algorithm to make CPR more effective
March 20, 2018 - Diabetes medication reduces chance of late miscarriage, premature birth among women with PCOS
March 20, 2018 - SSRIs may be more effective option for treating anxious youth, UC research shows
March 20, 2018 - Antibiotics could benefit women suffering from chronic bladder pain
March 20, 2018 - Health Highlights: March 16, 2018
March 20, 2018 - Interventional Radiology Has a Problem of ‘Unseen’ Value
March 20, 2018 - Antibodies show effectiveness for HIV prevention and promise for treatment and cure
March 20, 2018 - New 3-D-printed technology will improve radiology training
March 20, 2018 - New study identifies key role for particular gene in 16p11.2 deletion syndrome
March 20, 2018 - Red and processed meat increase the risk of liver disease
March 20, 2018 - 50% of Australians do not brush teeth twice a day
March 20, 2018 - American Gene Technologies receives second immuno-oncology patent
March 20, 2018 - Study finds no link between long-term violent video game play and adult aggression
March 20, 2018 - Weight loss surgery widely underutilized among young patients with severe obesity
March 20, 2018 - Scientists uncover new answers to cell aging in children with rare, fatal disease
March 20, 2018 - The Pistoia Alliance Calls for Greater Life Sciences Collaboration to Build the ‘Lab of the Future’
March 20, 2018 - Morning Break: Psychopathic Thought; Americans Flout Zzz’s; Farm to Pharma
March 20, 2018 - Perceptions of old age change as we age
March 20, 2018 - New standards for public involvement in research launched across the UK
March 20, 2018 - Whole Genome Sequencing used as diagnostic solution for TB
March 20, 2018 - Researchers show how two cancer genes work together to trigger leukemia
March 20, 2018 - Scientists discover basic molecular mechanism that helps understand how ALS works
March 20, 2018 - Multi-center study to evaluate promising new intervention for upper limb dysfunction after SCI
March 20, 2018 - Researchers develop technology to program DNA for delivering cancer drugs
March 20, 2018 - Northwestern scientists bring precision medicine to rheumatoid arthritis
March 20, 2018 - Research suggests possible link between heading a soccer ball and brain imbalance
March 20, 2018 - Robocall increases diabetic retinopathy screening rates among poor minorities
March 20, 2018 - INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Infantile Spasms
March 20, 2018 - Little Talk Between Docs and Patients Pre-PSA Screen
March 20, 2018 - Women GPs bring remote care to rural Pakistan
March 20, 2018 - Adults skipping vaccines may miss out on effective new shingles shot
March 20, 2018 - Suppressing emotions appears to reduce negative memories
March 20, 2018 - Epidural stimulation can safely, effectively normalize blood pressure in patients with SCI
March 20, 2018 - ‘Fast track’ project shows promising results in cancer whole genome analyses
March 20, 2018 - Advanced insulin pump system can also manage type 1 diabetes in children, study shows
March 20, 2018 - Flu risk less on flights if in a window seat finds study
March 20, 2018 - Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53
March 20, 2018 - Post-Transplant Fatty Liver Disease on the Rise
March 20, 2018 - New mutation linked to ovarian cancer can be passed down through dad
March 20, 2018 - Alex’s experiences of living with rare genetic disease
March 20, 2018 - Scotland study aims to offer precise diagnoses for people with rare genetic diseases
March 20, 2018 - Stem cell treatment may help rejuvenate ovaries, avoid effects of premature menopause
March 20, 2018 - FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
March 20, 2018 - Death Strikes Young in RA
March 20, 2018 - Quiescent cells also mutate
March 20, 2018 - Stem cell-derived ocular cells treat severe AMD
March 20, 2018 - Mediterranean diet appears to be good for postmenopausal women’s bones and muscles
March 20, 2018 - Scientists discover rare childhood liver cancer’s ability to metastasize to the brain
March 20, 2018 - Treating metastatic breast cancer with immunotherapy
March 20, 2018 - The 5:2 diet could have beneficial impact on important risk markers for cardiovascular disease
March 20, 2018 - Congress tackles the opioid epidemic. But how much will it help?
March 20, 2018 - Neanderthals Just Part of the Evolutionary Puzzle
March 20, 2018 - Higher Mortality With Surgery for Early NSCLC
March 20, 2018 - Researchers go skin deep to explore what causes wrinkles
March 20, 2018 - E-cigarette use linked to fat accumulation in the liver
CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

image_pdfDownload PDFimage_print

CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant® technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant® is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

The trial is designed to assess the safety, tolerability and immunomodulating effects of CV8102, a drug candidate developed with CureVac’s RNAdjuvant® technology. The trial includes a dose escalation and several expansion cohorts, with plans to investigate CV8102 in combination with anti-PD-1 therapies.

CureVac’s RNAdjuvant® (CV8102) is a potent immunomodulator designed to expand the effects of immuno-oncology treatments and prophylactic vaccines for the prevention of infectious diseases. In a previous Phase I study in healthy volunteers, CV8102 appeared safe and was shown to increase antigen-specific immune responses when combined with a licensed rabies vaccine.

Ulrike Gnad-Vogt, M.D., CMO of CureVac, commented, “The initiation of this study is a significant advancement for CureVac as it showcases our innovative approach to product development by leveraging our RNA platform. CV8102 has been shown to be an effective immunomodulator that results in significant, innate immune activation at the injection site, ultimately facilitating tumor rejection. Given this, we believe CV8102 is ideally suited for treating tumors via direct, intratumoral injection. We are looking forward to testing CV8102 for the first time in cancer patients and establishing its ability to trigger systemic immune responses via local injection, in particular in combination with a systemic checkpoint blockade.”

The Phase I clinical study is targeting patients with superficially accessible tumors of several different histologies and is aiming to find a safe and tolerated dose with or without concomitant systemic checkpoint inhibition. As secondary and/or exploratory endpoints, the study will evaluate signals of objective tumor response, and changes in treatment-induced effects of CV8102 on systemic immune parameters, tumor immune cell infiltration and other peripheral biomarkers of interest.​



Posted in: Drug Trial News | Device / Technology News | Medical Condition News

Tags: Antigen, Biotechnology, Cancer, Cell, Drugs, Infectious Diseases, Molecule, Oncology, RNA, Tumor, Vaccine

Tagged with:

About author

Related Articles